It's Never Too Late To Intensify: Upstream Process Intensification

As bioprocessing costs rise and product margins shrink, the need for flexible, efficient manufacturing strategies is more urgent than ever. Nearly half of protein therapies are produced at low volumes, and the complexity of bi- and multispecific mAbs adds further pressure on facility design and process scalability. Process intensification (PI) offers a path forward—reducing costs, improving access to medicines, and supporting sustainability goals. Early decisions around cell line, media, and culture mode are pivotal. Explore how a unified cell line and media platform can streamline transitions between fed-batch and perfusion, and how technologies like Ambr® 250 Perfusion and digital simulation tools can accelerate development.

Watch to learn how early upstream intensification can set the stage for robust scale-up, automation, and end-to-end process integration.